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Tibolone is a drug used as a hormonal repository and is very important due to its characteristic of helping to reduce the symptoms 
triggered by the hormonal alteration during the climacteric period. Although widely used, the Brazilian Pharmacopoeia does not 
have any information about this hormone. In the literature, only studies with methodologies using high performance liquid 
chromatography for drug quantification were found. Thus, this study aimed to develop and validate analytical method using UV 
spectrophotometry for quality control of Tibolone in capsule pharmaceutical form. The present study followed the validation 
parameters present in RDC 166/2017 and ICH Q2 (R1), with acetonitrile as solvent and 225 nm as wavelength. Linearity showed 
a correlation coefficient higher than 0.99, precision presented a mean of 97.81% and accuracy reached a recovery percentage 
average of 97.18%. It was concluded that the method can be used in the quality control of Tibolone capsules, besides having a low 
cost and a less complex methodology and easier to perform compared to HPLC. 
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Introduction 
Tibolone is known to be a hormonal repository that has great 
influence in the prevention of bone loss that usually happens 
during the climacteric and in the treatment of the symptoms 
caused by the hormonal alteration. It has estrogenic, 
androgenic and progestogenic activity. Through the 
progestogenic activity, the drug provides a protective effect 
on the endometrium and breasts (1). 
The increase in the woman's life expectancy has had a great 
impact on the health of the female population and in many 
cases it is essential to adopt measures aimed at a better 
quality of life during and after the climacteric (2).  
Discussions about hormone replacement therapy began 
around the 1960s, where, for all women who were going 
through the menopause period, estrogen therapy was 
prescribed, which itself caused several complications due to 
the increased endometrial level. In the 1980s, the protective 
characteristic caused by substances that mimicked the 
protective effect of progesterone was discovered, and in 
1990 the first studies were carried out showing that hormone 
replacement therapy could aid in the reduction or 
disappearance of hormonal alterati on symptoms. However, 
it was only in 2002 that the prescription of hormone 
replacement therapies was initiated, only when the really 
needed intervention of medication was verified and not only 
for the reduction of the symptoms. (3).  
After oral administration, the absorption of Tibolone is 
effected rapidly, due to its being widely absorbed, besides 
having rapid metabolization. Its maximum concentration in 
the organism is obtained between 1 - 4 hours after the 
administration. Part of the excretion occurs through the 
urine, but most of it is eliminated by the feces. (4). 
The various changes that have been occurring commonly in 
the pharmaceutical industry have strengthened the need for 
innovation and quality assurance, mainly due to the great 
competitiveness in the sector. In this sense, quality control is 
no longer seen as a bureaucratic collection, becoming one of 
the most important processes of obtaining a pharmaceutical 
form, seeking to guarantee quality, effectiveness, safety and 
in response to consumer confidence. (5). 
 
 
                  Figure 1. Chemical structure of Tibolone. 
 
The need to perform a quality control that ensures greater 
efficiency, effectiveness and safety is related to the 
uniformity of procedures, processes, equipment, materials, 
activities or systems, making the development of efficient 
and fast analytical methodologies a practice of extreme 
value, providing greater security for users and analysts. (6). 
Since 2000, the increase in the number of drugs handled in 
Brazil, mainly due to the need for specific formulation and 
the lower cost, has led to a greater concern of the Agência 
Nacional de Vigilância Sanitária (ANVISA) regarding the 
quality of the products that are being produced and marketed 
by manipulation pharmacies. The first step was given 
through the publication of RDC No. 33 on 19 April 2000, 
which specified instructions on good handling practices in 
pharmacies. (7).  
Currently, RDC No. 67, dated October 8, 2007, is in force, 
which aims to ensure the safety and quality of formulations 
produced in handling pharmacies throughout Brazil, in 
addition to establishing quality control criteria for facilities, 
equipment, human resources and procedures. (8). 
Spectrophotometry is related to the electromagnetic 
absorption of molecules, and to the concentration and 
structure of molecules. 
UV spectrophotometric methods are widely used in the 
development and validation of analytical methods for drug 
analysis. It is important to choose a solvent that does not 
interfere with the analysis wavelength (9). 
Based on this knowledge, the present study aimed to 
develop and validate a simple, fast and low-cost analytical 
methodology for the quality control of Tibolone in capsule 
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pharmaceutical form, based on UV spectrophotometry, since 




The Tibolone raw material (Lot: TBL / 217008), with 
declared content of 100%, used as reference standard and 
2.5 mg capsules were purchased in a pharmacy of 
manipulation, located in São Leopoldo, Rio Grande do Sul. 
The excipients used in the preparation of the capsules were 
corn starch and silicon dioxide. The solvents used for the 
development of the method were: acetonitrile (Synth, Vetec, 
Chemical Group), ethanol (Vetec) and methanol (Synth) PA 
grade. 
Equipment 
The equipment used were UV-vis spectrophotometer model 
UV-1600 (Pro-tools) and spectrophotometer model UV-
2600 (Shimadzu). The glassware used during the 
experiments were made available by the Universidade do 
Vale do Rio dos Sinos and the tests carried out in the 
chemistry laboratories of the University and the Nutrifor 
Technological Institute. 
Development of the Methodology 
Based on the Tibolone monograph available in the British 
Pharmacopoeia (10), the acetonitrile, ethanol and methanol 
solvents were initially selected for solubilizing the drug. 
To carry out the initial tests, the published study regarding 
the development and validation of high-performance liquid 
chromatography (HPLC) methods for Tibolone were used. 
 In the chromatographic analyzes the wavelength was 204 
nm and 205 nm and the solvents employed as mobile phase 
were acetonitrile and water (65:35 v/v), (60:40 v/v), and 
acetonitrile, water and methanol (60:30:10 v/v). (11,12,13). 
A secondary standard was then prepared to test different 
concentrations to determine the one to present the most 
satisfactory results. The sample preparation was perfomed 
through a pool of 20 capsules. After preliminary tests, a 
spectrophotometer scan was performed between the 
wavelengths of 200 and 400 nm using solutions of each of 
the solvents mentioned above with reference standard, 
excipients and 200 μg/mL sample to verify the maximum 
absorption of the drug and possible interferences caused by 
the excipients. After defining the most suitable solvent to 
perform the method, it was to determine the most 
appropriate sample concentration. 
 
Validation 
To perform the validation of the analytical method, the 
guidelines presented in RDC 166/2017 of ANVISA (14) and 
the International Conference on Harmonization (15) were 
followed. The parameters evaluated were: specificity, 




The sample solutions, the reference standard and the 
simulated mixture of the excipients were scanned at the 
same concentration in the 200 to 400 nm range in order to 
evaluate their interference in the quantification of the drug. 
An amount of powder equivalent to 10 mg of Tibolone was 
used to prepare the excipient and sample solution, whereas 
10 mg of the reference standard was used for the raw 
material solution. 
Linearity 
Linearity was evaluated through the construction of three 
analytical curves ranging from 60 to 140% of the work 
concentration. For this purpose, a stock solution of 
secondary standard (1.0 mg/mL) was prepared from which 
aliquots were drawn and diluted in 10 mL volumetric flasks 
with acetonitrile, resulting in concentrations of 120, 160, 
200, 240 and 280 μg/mL. It was decided to use 10 mL 
volumetric flasks in the dilutions to avoid waste and 
minimize the generation of waste due to the need to use 
organic solvent. Statistical analysis of the data was 
performed through ANOVA with a 95% confidence interval. 
Precision 
Precision was expressed by repeatability, intermediate 
precision or reproducibility. Samples were prepared 
regardless. (16). 
To evaluate the repeatability, six independent samples were 
prepared at a concentration of 200 μg/mL and the 
absorbance readings were performed in the 
spectrophotometer. In the intermediate precision the same 
procedure of preparation of six independent samples of the 
same concentration was carried out by a different analyst 
and on different days. The result was expressed by the 
relative standard deviation value (RSD%). 
 
Accuracy 
Accuracy was evaluated by the method of addition of 
standard in sample through 9 determinations, contemplating 
the linear interval of the analytical method. Three levels of 
addition (25, 50 and 75% of the reference standard) in the 
sample were performed from the starting point of the curve 
of 120 μg/mL, in triplicate.  
For the calculation of the recovery percentage, the formula 
available in RDC 166 of 2017 was used (14). 
 
Experimental mean concentration Recovery = 
 
           Standard added - Sample concentration   X 100 




The verification of robustness was achieved by the 
realization of linearity with variation of the solvent brand 
and realization of the method in two different laboratories 
and with different equipments. 
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Results and discussion 
Based on the spectra obtained by ultraviolet region 
scanning, the wavelength of 225 nm was selected for 
validation of the analytical method, taking into account the 
maximum absorption of Tibolone and the non-interference 
of the excipients at this wavelength. 
From the tests performed it was observed that it was 
possible to work by weighing the minimum amount of 
reference standard (10 mg) using a small volume of organic 
solvent to prepare the sample. 
Through the spectra obtained in the analysis of the solvents, 
it was verified that ethanol and methanol have absorption 
peaks in wavelength very similar to the one of the Tibolone, 
being able to cause interferences in the readings of 
absorbance of the drug, whereas the acetonitrile does not 
present peaks that can interfere in the analysis of the drug, 
basing its choice for development and validation of the 
method. 
The specificity evaluation was performed by analyzing the 
spectra of the sample solutions, the reference standard and 
the simulated mixture of the excipients (200 µg/ mL) in the 
range from 200 to 400 nm, demonstrating that the excipients 
used in the capsule formulation did not interfere in the 
quantification of Tibolone in the wavelength of 225 nm, as 
shown in Figure 2. 
 
Figure 2: Absorbance of Tibolone sample, secondary standard and 
excipients (200 µg/ mL) in acetonitrile. 
 
 
The method was linear with R2 of 0.9992 and correlation 
coefficient (r) of 0.9996, and the recommended value is a 
correlation coefficient value higher than 0.99. The equation 
of the line was y = 0.0021x + 0.0076 (Figure 3) and in the 
statistical analysis by ANOVA an F value of 0.37 was 
found, which was lower than the tabulated value (4.53). 
 
Figure 3: Linearity analytical curve. 
 
The repeatability was evaluated by the preparation of six 
independent samples in the working concentration, while in 
the intermediate precision another analyst was responsible 
for the preparation of the six samples. From the results 
obtained, the values of RSD% were calculated. The 
repeatability and intermediate precision presented RSD 
values of 2.32% (day 1), 2.65% (day 2) and 2.92% of RSD 
intraday (Table 1). The new resolution of ANVISA (14) 
does not specify a reference value, but the old resolution 
(17) recommended a RSD value less than 5%. 
Accuracy was assessed by adding standard in sample and 
determined by recovery percentage. According to Table 2, 
the results obtained were satisfactory, obtaining recovery 
percentages close to 100%. The accuracy values are between 
95 and 105%, assigning an acceptable characteristic for this 
parameter. 
The method remained robust even when the solvent brand 
variation was performed and also through the results 
obtained from the tests performed in two different 
laboratories and with different glassware and equipment, 
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Table 1: Precision and intermediate precision results obtained by analysis UV spectrophotometric. 















1 95.55% 97.00% 99.10% 93.03% 94.69% 97.92% 2.32% 
2 101.19% 102.23% 97.30% 100.53% 95.22% 99.91% 2.65% 
RSD Intraday      2.92% 
RSD: Relative Standard Deviation. 
 
Table 2: Percentage values of Tibolone recovery by adding pattern to sample by UV spectrophotometry method. 
 Tibolone (µg/ mL) Average Content (%) 
25% 34.66 27.44 28.44 30.18 100.6 
50% 58.22 56.44 57.77 57.47 95.78 
75% 86.55 84.68 85.72 85.65 95.16 
Content: Recovery percentage. 
 
Conclusion 
Through the analysis of the results, it was possible to verify 
that the developed method meets the parameters required for 
validation, obtaining proof of specificity, linearity, 
precision, accuracy and robustness. Since it is proven that 
the methodology is satisfactory, it is indicated the use of the 
same to perform quality control of Tibolone in several areas, 
but mainly in handling pharmacies and laboratories that do 
not have sophisticated equipment like a liquid 
chromatograph  and need simpler methodologies as well 
enabling lower cost and faster analysis, however that are 
effective and accurately portray the results obtained. 
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